Patel, V., Keating, M. J., Wierda, W. G., & Gandhi, V. (2015). Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase-activating compound with ibrutinib in chronic lymphocytic leukemia. Leuk Lymphoma.
Citação norma ChicagoPatel, Viralkumar, Michael J. Keating, William G. Wierda, and Varsha Gandhi. "Preclinical Combination of TP-0903, an AXL Inhibitor and B-PAC-1, a Procaspase-activating Compound With Ibrutinib in Chronic Lymphocytic Leukemia." Leuk Lymphoma 2015.
Citação norma MLAPatel, Viralkumar, Michael J. Keating, William G. Wierda, and Varsha Gandhi. "Preclinical Combination of TP-0903, an AXL Inhibitor and B-PAC-1, a Procaspase-activating Compound With Ibrutinib in Chronic Lymphocytic Leukemia." Leuk Lymphoma 2015.